SLC5A2 and type 2 diabetes mellitus: Although in recent decades cardiovascular outcomes have improved for adults with or without T2D, decreasing the burden associated with HF by treating classical cardiovascular risk factors has proven to be difficult and thus remains a major public health priority.2 Accordingly, the introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors offers promise to mitigate cardiorenal disease in people with or without T2D.